Logo

Xeris’s Recorlev (levoketoconazole) Receives the US FDA’s Approval for Endogenous Hypercortisolemia in adult With Cushing’s Syndrome

Share this

Xeris’s Recorlev (levoketoconazole) Receives the US FDA’s Approval for Endogenous Hypercortisolemia in adult With Cushing’s Syndrome

Shots:

  • The approval is based on the P-III (SONICS) & (LOGICS randomized-withdrawal) studies to evaluate Recorlev vs PBO in 166 patients with endogenous hypercortisolemia with Cushing’s syndrome. The product is expected to launch in Q1’22
  • Both studies met its 1EPs & 2EPs i.e., reduction & normalization rate of mean UFC without a dose increase & confirmed the efficacy & safety in normalizing & maintaining therapeutic response
  • Recorlev is a cortisol synthesis inhibitor & has received ODD from the US FDA & EMA for the same indication. The company has launched the Xeris CareConnection program & provide access to patients including financial assistance, one-on-one support & educational resources

Ref: Xeris | Image: Xeris

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions